Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 04 2017 - 4:05PM
Business Wire
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a
biopharmaceutical company focused on delivering innovative
therapies to patients with kidney disease through the biology of
hypoxia-inducible factor (HIF), today announced that the Company
granted seven newly hired employees options to purchase an
aggregate of 33,000 shares of Akebia's common stock with a per
share exercise price of $19.67, the closing price on the grant
date. These options will vest as to 25% of the total number of
shares subject to the option on the first anniversary of the grant
date. The remaining 75% of shares will vest ratably on the first
day of each calendar quarter over the next three years. The stock
options were inducements material to these new employees entering
into employment with the Company, and issued in reliance on NASDAQ
Listing Rule 5635(c)(4).
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company
headquartered in Cambridge, Massachusetts, focused on delivering
innovative therapies to patients with kidney disease through
hypoxia-inducible factor biology. Akebia's lead product candidate,
vadadustat, is an oral, investigational therapy in development for
the treatment of anemia related to chronic kidney disease in both
non-dialysis and dialysis patients. Akebia's global Phase 3 program
for vadadustat, which includes the PRO2TECT studies for
non-dialysis patients with anemia secondary to chronic kidney
disease and the INNO2VATE studies for dialysis-dependent patients,
is currently ongoing. In addition, the Company has initiated the
Phase 2 FO2RWARD study of vadadustat in dialysis-dependent chronic
kidney disease patients who are hyporesponsive to
erythropoiesis-stimulating agents (ESAs), and expects to commence
the Phase 3 TRILO2GY study to further evaluate a three-times-weekly
dosing regimen for vadadustat. For more information, please visit
our website at www.akebia.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171004006196/en/
Akebia:Theresa McNeely, 617-844-6113SVP, Corporate
Communicationsand Investor Relationstmcneely@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2023 to Apr 2024